Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders

用于诊断和治疗婴儿出血性疾病的抗血小板抗体工程

• 批准号: ARC : LP0221344
• 负责人: Christopher Marquis
• 金额: $ 6.76万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2002
• 资助国家: 澳大利亚
• 起止时间: 2002-01-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/engineering-anti-platelet-bleeding-disorders/67716
• 关键词: Engineering; anti; platelet; antibodies; diagnosis

Engineering of anti-platelet antibodies for the diagnosis and therapy of infants with bleeding disorders. Foeto-maternal alloimmune thrombocytopenia (FMAIT) is a serious clinical condition where infants suffer potentially fatal bleeding disorders from 14 weeks gestation to 1-2 weeks post delivery. The cause of the disease is through maternal antibodies destroying foetal platelets. Our aim is to produce human antibodies, which will be used as diagnostic agents to screen for the condition in pregnant women, and to further develop such antibodies for therapy. Identification of mothers at risk of FMAIT and the development of a specific therapy are vital to the management and prevention of this serious condition.

抗血小板抗体工程在婴儿出血性疾病诊断和治疗中的应用。胎-母同种免疫性血小板减少症（FMAIT）是一种严重的临床疾病，婴儿从妊娠14周到分娩后1-2周患有可能致命的出血性疾病。这种疾病的病因是通过母体抗体破坏胎儿的血小板。我们的目标是生产人类抗体，作为筛查孕妇病情的诊断试剂，并进一步开发用于治疗的抗体。识别有FMAIT风险的母亲和开发特定的治疗方法对于管理和预防这一严重疾病至关重要。